Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study

Clinical and Experimental Nephrology
Haibo YuAi Peng

Abstract

To compare the safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with estimated glomerular filtration rate (eGFR) 20-60 mL/min/1.73 m2. This study was a single-centered, parallel-grouped, randomized clinical trial (RCT). We randomly assigned hyperuricemia participants with eGFR 20-60 mL/min/1.73 m2 into benzbromarone and febuxostat treatment group. Drugs were adjusted by titration from small doses. Seventy-three eligible participants enrolled, 66 subjects (33 in each group) were included finally for analysis. When compared to baseline, serum uric acid (SUA) decreased significantly after treatment in both groups, but no differences were detected among all the follow-up points. After 12-month treatment, eGFR did not have significant change in both groups. In the benzbromarone group, kidney stones in one case increased in quantity. In the febuxostat group, kidney stones in one case became smaller in size and in two cases vanished completely. Both drugs did not increase myocardial enzymes significantly after the treatment. In addition, hemoglobin increased significantly in the two groups (p < 0.05). Benzbromarone and febuxostat could reduce SUA and maintain renal function in chronic kidney disease (CKD) ...Continue Reading

References

Nov 27, 1986·The New England Journal of Medicine·B EttingerT Williams
Jan 1, 1994·Advances in Experimental Medicine and Biology·U GresserM Gross
Dec 12, 2002·Endocrinology and Metabolism Clinics of North America·Carsten M Sorensen, Paramjit S Chandhoke
Oct 28, 2005·Journal of the American Society of Nephrology : JASN·Duk-Hee KangRichard J Johnson
Dec 7, 2007·Kidney International·G C Curhan, E N Taylor
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Jul 16, 2011·Clinical Journal of the American Society of Nephrology : CJASN·David S Goldfarb
Oct 24, 2012·Advances in Chronic Kidney Disease·Tapan H Mehta, David S Goldfarb
Jan 4, 2013·American Journal of Physiology. Renal Physiology·Eun-Sun RyuDuk-Hee Kang
Sep 18, 2013·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Bhadran BoseDavid W Johnson
Apr 2, 2014·Journal of Nephrology·Omotayo Arowojolu, David S Goldfarb
Dec 3, 2014·Atherosclerosis·Maria Giulia BattelliAndrea Bolognesi
Oct 16, 2015·BMC Musculoskeletal Disorders·Ashika ChhanaNicola Dalbeth
Oct 17, 2017·American Journal of Nephrology·Hernan Rincon-CholesMichael B Rothberg
Nov 15, 2017·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Anand SrivastavaSushrut S Waikar
Nov 16, 2017·Oxidative Medicine and Cellular Longevity·Vassilios LiakopoulosPeter R Mertens
Mar 3, 2018·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Richard J JohnsonGlenn M Chertow
Mar 13, 2018·The New England Journal of Medicine·William B WhiteUNKNOWN CARES Investigators

❮ Previous
Next ❯

Citations

Aug 9, 2019·Advances in Rheumatology·Valderilio Feijó AzevedoEduardo Dos Santos Paiva
Mar 28, 2019·Expert Opinion on Drug Safety·Larysa StrilchukArrigo Fg Cicero
Sep 26, 2020·Renal Failure·Tadej PetreskiSebastjan Bevc
Oct 14, 2020·The Korean Journal of Internal Medicine·Yousuf WaheedDong Sun
Sep 29, 2021·Clinical Rheumatology·Tim LThA JansenJanssen Matthijs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.